Early safety check: how do livers handle new medication?
NCT ID NCT06916078
Summary
This early-stage study aims to understand how a new drug called lepodisiran is processed by people with different levels of liver function. Researchers will compare how the drug moves through the body and its safety in 33 participants, some with healthy livers and some with mild to severe liver impairment. The goal is to gather basic safety and dosing information for future research.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
American Research Corporation at Texas Liver Institute
RECRUITINGSan Antonio, Texas, 78215, United States
Contact Phone: •••-•••-••••
Contact
-
CRU Early Phase Unit
RECRUITINGKistarcsa, H-2143, Hungary
Contact Phone: •••-•••-••••
Contact
-
Clinical Pharmacology of Miami
RECRUITINGMiami, Florida, 33014-3616, United States
Contact Phone: •••-•••-••••
Contact
-
Orlando Clinical Research Center
RECRUITINGOrlando, Florida, 32809, United States
Contact Phone: •••-•••-••••
Contact
Conditions
Explore the condition pages connected to this study.